ID   HROG02-CIITA
AC   CVCL_C6JW
DR   PRIDE; PXD020079
DR   Wikidata; Q116049504
RX   PubMed=33592498;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:7067; CIITA.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Omics: HLA class II peptidome analysis by proteomics.
CC   Derived from site: In situ; Brain, right parieto-occipital lobe.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4U38 ! HROG02
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 19-12-24; Version: 5
//
RX   PubMed=33592498; DOI=10.1074/mcp.RA120.002201; PMCID=PMC8724627;
RA   Forlani G., Michaux J., Pak H., Huber F., Lauret Marie-Joseph E.,
RA   Ramia E., Stevenson B.J., Linnebacher M., Accolla R.S.,
RA   Bassani-Sternberg M.;
RT   "CIITA-transduced glioblastoma cells uncover a rich repertoire of
RT   clinically relevant tumor-associated HLA-II antigens.";
RL   Mol. Cell. Proteomics 20:100032.1-100032.21(2021).
//